



Optimal Advanced HIV Disease Project

Dr. Luis Pizarro

Team Lead, Unitaid

28 July 2020



HIV LEARNING NETWORK
The CQUIN Project for Differentiated Service Delivery

Agenda

01

Introduction to Unitaid

02

Overview of Optimal AHD Project

03


Achievements to date

04

Rationale for this AHD workshop


Introduction to Unitaid (1)

Development assistance for health (\$B)




Source: IHME (Institute for Health Metrics and Evaluation), *projections

Introduction to Unitaid (2)




Introduction to Unitaid (3)

49 grants



■ HIV & co-infections ■ TB ■ Malaria ■ Cross-cutting

\$1.3 billion



■ HIV & co-infections ■ TB ■ Malaria ■ Cross-cutting

Unitaid's portfolio as of January 2020

Overview Optimal AHD Project (1)

1/3rd

Of people initiating ART in Sub-Saharan Africa have AHD

Challenge: There is an ineffective global response to advanced HIV disease (AHD), and an urgent need to accelerate access to critical, life-saving products for diagnosis, prevention, and treatment of AHD.

Unitaid Advanced HIV Disease Initiative

CHAI Implementation Period
January 2019 – December 2020



Reduce the price of priority health products through supply-side market interventions



Accelerate product introduction and build demand for AHD commodities through **catalytic procurement** and adoption and rollout support



Coordinate procurement and provide market visibility for AHD commodities

The AHD initiative is supported by a strong coalition of partners, including Global Fund, PEPFAR, EGPAF and MSF. Unitaid is calling on all partners to contribute to these efforts to prevent needless HIV deaths.

Project Countries

Malawi, Nigeria, South Africa, Tanzania, Uganda, Botswana and Lesotho



Priority Health Products

Diagnostics

- CD4
- TB urine-LAM
- CrAg LFA rapid test


Therapeutics

- TB prevention therapy
- Amphotericin B (classic and liposomal)
- Flucytosine
- Fluconazole



Overview Optimal AHD Project (3)

Unitaid's Global Partnership on Advanced HIV Disease



Achievements to date

- ✓ **Established an Early Market Access Vehicle (EMAV) and negotiated a ceiling price agreement** for the Omega VISITECT® CD4 Advanced Disease test to facilitate rapid product introduction
- ✓ Kicked off **catalytic procurement for AHD** commodities, reducing the pricing of flucytosine (5FC), and supported countries to develop AHD programs and implementation plans
- ✓ **Generated momentum in the AHD market**, through the development of a toolkit, established the Implementation Steering Committee (ISC), and kicked-off of the AHD Community Advisory Board

Rationale for this AHD Workshop

- **Facilitate collaboration** across multiple key partners and countries to leverage core strengths in commodity access and service delivery to ensure a holistic approach to AHD planning and implementation in countries.
- **Foster cross-learning** among participating Ministries of Health through sharing lessons learnt in addition to discussing tailored approaches to in-country activities.
- **Keep focus on AHD globally** to prevent senseless deaths.

